Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase NA 1Phase EARLY_PHASE1 1

Status

Unknown 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

EGFR Positive Non-small Cell Lung Cancer 1

Interventions

fludarabine 2Interleukin-2 2Cyclophosphamide 2toripalimab 1lenvatinib 1epigallocatechin gallate 1avelumab 1Zinc 1Tissue Banks 1Quercetin 1Pemetrexed 1Paclitaxel 1Optical Fibers 1Metformin 1Ethiodized Oil 1Docetaxel 1Dihematoporphyrin Ether 1Cisplatin 1Carboplatin 1Blood Specimen Collection 1Biopsy, Needle 1Bevacizumab 1Albumin-Bound Paclitaxel 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × OTHER_GOV × toripalimab × Clear all
NCT06208033 2024-01-17

SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)

Fujian Cancer Hospital

Phase EARLY_PHASE1 Unknown
40 enrolled
Thoracic

EGFR Positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡